

# BioNTech and Medigene Announce Global Collaboration to Advance T Cell Receptor Immunotherapies Against Cancer

**Torreya advised Medigene on this transaction**

Mainz/Martinsried/Munich, Germany, February 21, 2022

BioNTech SE (Nasdaq: BNTX, "BioNTech") and Medigene AG (FSE: MDG1, Prime Standard, "Medigene"), a clinical-stage immuno-oncology company focusing on the development of T cell immunotherapies, announced that they have entered a multi-target research collaboration to develop T cell receptor (TCR) based immunotherapies against cancer. The initial term of the collaboration is three years.

Medigene will contribute its proprietary TCR discovery platform for the development of TCRs against multiple solid tumor targets nominated by BioNTech. Medigene's automated, high throughput TCR discovery platform is designed to bypass central tolerance to yield high affinity TCRs. T cell therapy has become a disruptive medical innovation in the treatment of patients with cancer. Engineered TCR-modified T cells (TCR-T cells) are reprogrammed to express a TCR that can recognize specific antigens only present on tumor cells, thereby enabling a precise and potent immune response to attack a patient's tumor.

BioNTech will acquire Medigene's next generation preclinical TCR program, which combines TCR-4 of Medigene's MDG10XX program targeting PRAME with Medigene's proprietary PD1-41BB switch receptor technology. BioNTech will also obtain the exclusive option to acquire additional existing TCRs in Medigene's discovery pipeline and will receive licenses to the company's PD1-41BB switch receptor and precision pairing library. This has the potential to augment TCR cell therapy efficacy and can be applied to all BioNTech cell therapy programs.

Under the terms of the agreement, Medigene will receive €26 million upfront, as well as research funding for the period of the collaboration. BioNTech will be responsible for global development and hold exclusive worldwide commercialization rights on all TCR therapies resulting from this research collaboration. Medigene will be eligible to receive development, regulatory and commercial milestone payments up to a triple digit million EUR amount per program in addition to tiered deferred option payments on global net sales for products based on TCRs arising from the collaboration and royalties on products utilizing at least one of the licensed technologies.

Torreya represented Medigene on this transaction, which highlights Torreya's strength in advising oncology companies, in addition to our strong relationships in the biopharma sector. Torreya has advised biotech companies on almost \$2 billion in combined transaction value in the past 24 months.

## ABOUT ABOUT MEDIGENE AG:

For more information about Medigene, please see: [www.medigene.com/home](http://www.medigene.com/home)

## ABOUT BIONTECH SE:

For more information about BioNTech, please see: [www.biontech.de](http://www.biontech.de)

## Deal Press Release

### Torreya Contacts

#### STEPHANIE LÉOUZON

Partner and Head of Torreya Europe | London Office

[stephanie.leouzon@torreya.com](mailto:stephanie.leouzon@torreya.com) | +44 (0) 207-451-4553 | [BIO](#)

#### KELLY CURTIN

Managing Director | London Office

[kelly.curtin@torreya.com](mailto:kelly.curtin@torreya.com) | +44 (0) 207-451-4564 | [BIO](#)

Torreya is a global advisory firm serving the life sciences industry. Please visit [torreya.com](http://torreya.com) for more information. Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. Torreya Partners LLC is a Delaware Limited Liability Company while Torreya Partners (Europe) LLP is a limited liability partnership, registered in England and Wales, registered number OC362930. Registered office: 15 Stratford Place, London W1C 1BE. Torreya Partners (Europe) LLP is authorized and regulated by the Financial Conduct Authority. The information contained in the email and/or its attachments is confidential and/or privileged and is for the sole use of the intended recipient(s). If you are not the intended recipient, please notify the sender immediately by reply and immediately delete this message and all its attachments. Any review, use, reproduction, disclosure or dissemination of the message or any attachment by an unintended recipient is strictly prohibited. Neither this message nor any attachment is intended as or should be construed as an offer, solicitation or recommendation to buy or sell any security or other financial instrument. This communication is for informational purposes only. All investments involve risks including loss of principal invested. Past performance does not guarantee future results or success. Torreya Capital and its representatives do not provide tax or legal advice and each tax and financial situation is unique. Investors should consult their tax and/or legal advisor for advice and information concerning their particular situation.

## medigene

Global multi-target collaboration to discover and develop TCR immunotherapies against cancer, acquisition of PRAME TCR

**BIONTECH**

**€26 million upfront**  
**+ research funding,**  
**milestones and royalties**  
February 2022